AKI Clinical Trial
Official title:
Association of Preadmission Metformin Exposure and Incidence of Acute Kidney Injury Within 7 Days in Patients With Type 2 Diabetes in Intensive Care Unit: a Retrospective Cohort Study
NCT number | NCT04631289 |
Other study ID # | met on AKI |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2020 |
Est. completion date | November 10, 2020 |
Verified date | November 2020 |
Source | Second Affiliated Hospital of Guangzhou Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
More than 50% of ICU patients suffer from Acute kidney injury (AKI). Metformin shows protective properties in kidney disease. Our study aimed to validate AKI incidence among diabetes patients in the ICU with or without preadmission metformin exposure. We included non-AKI patients with type 2 diabetes in Medical Information Mart for Intensive Care (MIMIC)-III database. Incidence of AKI and mortality were compared between those with and without preadmission prescriptions.
Status | Completed |
Enrollment | 3841 |
Est. completion date | November 10, 2020 |
Est. primary completion date | September 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 90 Years |
Eligibility | Inclusion Criteria: - type 2 diabetes - >16 years old and <90 years old - without AKI Exclusion Criteria: - CKD - data error - type 1 diabetes - diabetes patients with pregnancy - no metformin record - with AKI |
Country | Name | City | State |
---|---|---|---|
China | SAHGuangzhouMU | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital of Guangzhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of AKI | AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. | within 7days in the ICU |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04112953 -
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
|
||
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
Recruiting |
NCT04597034 -
Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19
|
N/A | |
Completed |
NCT04458571 -
Effect of CRRT Duration on Solute Removal
|
||
Recruiting |
NCT04114747 -
Renal Physiology During Continuous Renal Replacement Therapy
|
N/A | |
Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT05382078 -
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
Completed |
NCT04762524 -
The Impact of CRRT Modality on Filter Life
|
N/A | |
Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
Completed |
NCT04788394 -
Renal Involvement in Hospitalized Children With COVID-19
|
||
Recruiting |
NCT04474249 -
Follow-up of Critical COVID-19 Patients
|
||
Completed |
NCT04517630 -
Renal Biomarkers in AKI and COVID-19
|
||
Completed |
NCT04407156 -
Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
|
||
Recruiting |
NCT04895384 -
El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
|
||
Completed |
NCT03070353 -
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
|
Phase 2/Phase 3 |